GVR Report cover Nuclear Medicine Market Size, Share & Trends Report

Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-1-68038-086-6
  • Number of Report Pages: 170
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2021
  • Forecast Period: 2023 - 2030 
  • Industry: Healthcare

Nuclear Medicine Market Size & Trends

The global nuclear medicine market size was estimated at USD 10.02 billion in 2023 and is expected to grow at a compound annual growth rate of (CAGR) 11.8% from 2024 to 2030. The market is witnessing growth due to the presence of a robust product pipeline and favorable government initiatives to improve access to nuclear medicine. Currently, betalutin, omburtamab, yttrium-90 microspheres, PNT2003, 177Lu‑PNT2002, are some of the products under clinical trials. The market has been moderately impacted due to SARS-CoV-2. The operation of reactors has been largely classified as an essential service, given its criticality. Therefore, nuclear reactors were not shut down during the SARS-CoV-2 lockdown. For instance, under Section 71 of the Labour Act 66 of 1995 in South Africa, its SAFARI-1 reactor remained operational during the lockdown enforced in the country post March 2020.

U.S. Nuclear Medicine market size and growth rate, 2023 - 2030

Moreover, in an article published by ANSTO in May 2020, it was reported that since its reactor provides critical medicines, it had maintained its operations during the COVID-19 crisis, with its staff returning to campus and following strict social distancing measures. According to the American Cancer Society, the estimated incidence of prostate cancer is 268,490, and around 34,500 deaths in 2022 in the U.S. In addition, around 6 out of 10 patients diagnosed are men aged 65 years and older and rare in men under 40 years. Recently, in March 2022, the U.S. FDA approved Pluvicto (177Lu-PSMA-617) for the treatment of adults with metastatic prostate cancer. This approval is anticipated to drive market growth.

The presence of a favorable reimbursement scenario for radiopharmaceuticals in the U.S., is anticipated to boost the market growth. In 2020, the Center for Medical Services (CMS) offered USD 10 add on payment for Tc-99m derived from non-highly enriched uranium (HEU) for hospital outpatient service in addition to payment for imaging procedures. The initiatives, in turn led to greater patient access for much needed diagnostic nuclear medicines used for life-threatening diseases.

Increasing advancements in the diagnosis and treatment of diseases, and approval of new nuclear-medicine-based devices helps in addressing patients treatment needs. For instance, in September 2021, GE Healthcare announced the launch of novel scanner with new automated workflow feature that offers an exceptional view of cardiac anatomy and pathology to help physicians to decide the right treatment for a patient.

Market Concentration & Characteristics

Market growth stage is high, and pace of the market growth is accelerating. The radiopharmaceuticals is characterized by a high degree of innovation. This can be attributed to the advanced technologies and methodologies for transforming treatment practices. In the space, Novartis' milestone achievement with the FDA's approval for Pluvicto production at the Milburn facility in April 2023. This move is poised to shape the market landscape, reflecting a strategic response to the growing demand for advanced nuclear medicine solutions. The space witnesses a notable M&A activities by the leading players. Leading players are strategically joining forces to expand and enhance their services, gain access to new technologies, consolidate in the rapidly growing market, and address the increasing strategic importance of nuclear medicine.

Nuclear Medicine Market Concentration & Characteristics

The space is also subject to increasing regulatory scrutiny. Title 21 from the Code of Federal Regulations governs the use of radiopharmaceuticals in the U.S. The diagnostics and therapeutic applications of radiopharmaceuticals are covered separately under this title in Part 315 & Part 361, respectively. In addition, the Nuclear Regulatory Commission (NRC) regulates the use of radiopharmaceuticals in 37 states. The NRC authorizes the utilization and possession of radioactive source material, byproduct, and special nuclear material. The Center for Devices and Radiology Health (CDRH) governs the use of radiopharmaceuticals and the use of electron-emitting products, including medical devices.

Radiopharmaceuticals are also regulated by the Center for Drug Evaluation & Research (CDER), a division of the U.S. FDA. Furthermore, the FDA Modernization Act of 1997 was a major regulatory breakthrough that gave special attention to PET drugs that were earlier exempted from a few of the U.S. FDA requirements. Section 121 of the Modernization Act directed the FDA to establish CGMPs and suitable approval procedures for PET drugs. In 2009, the FDA published regulations that described CGMP standards for each PET drug manufacturer during the production (21 CFR part 212) and the guidance on PET drugs.

Radiopharmaceutical methods are more accurate than traditional diagnostic and treatment methods. However, higher price of radiopharmaceuticals is increasing the chances of usage of substitute products. Thus, the threat of substitution is expected to be moderate during the forecast period. Traditional chemotherapy agents and radiation therapy can be used, as these are comparatively cheaper substitutes for radiopharmaceuticals.

Product Insights

The diagnostic product segment held the highest market share of 72.71% in 2023 owing to presence of large patient base and availability of advanced technologies such as Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). According to the World Nuclear Association Analysis 2021, about 40 million nuclear medicine procedures are performed annually and the demand for radioisotopes increase by around 5% every year. A wide range radiotracers that are currently employed in diagnosis of tumors coupled with technological advancements are contributing to the growth of the market.

The therapeutic segment is further divide into alpha emitters, beta emitters, and brachytherapy. The robust product pipeline coupled with the approval and commercialization of nuclear medicine therapeutics may fuel the segment growth. For instance, in October 2021, the U.S. FDA approved and granted breakthrough designation to diffusing alpha-emitters Radiation Therapy (DaRT) for the treatment of patients suffering from recurrent glioblastoma multiforme (GBM). It is a standalone therapy when other therapies have failed to work in patients with GBM. Currently, radium (Ra-223) is the most widely used alpha emitter in therapeutics. Development of potential radioisotopes, such as Terbium (Tb-149), Bismuth (Bi-212), and Actinium (Ac-225) is expected to augment market growth.

Application Insights

Based on application, global nuclear medicine is divided into oncology, thyroid, neurology, cardiology, lymphoma, bone metastasis, endocrine tumors, and other markets, wherein, the oncology segment dominated the market in 2023. Cancer is one of the leading causes of death worldwide. Factors such as, unhealthy diet, bad habits like smoking, and lack of exercise are contribute in rising prevalence. Furthermore, rising investment in R&D of novel nuclear medicines for the treatment of cancer may contribute to segment growth. For instance, in January 2022, ITM Isotope Technologies Munich SE initiated COMPOSE phase 3 trial of177lu-edotreotide to evaluate the viability of product for treating patients with neuroendocrine tumors.

Global Nuclear Medicine Market share and size, 2022

The cardiology segment is expected to witness high growth over the forecast period due to the increasing demand for the diagnosis of CVD. In March 2021, Bracco Diagnostics Inc., entered into a partnership with CardioNavix, LLC aim at improving patient reach to novel cardiac PET imaging system. This new initiative enable provides patients an easy access to hospitals, physician, and diagnostic centers, for cardiac PET imaging. This program may reduce the upfront cost and risk of business loss by encouraging clinical practitioners to prescribe & avail this important diagnostic test.

End-use Insights

Based on end-use, hospitals segment dominated the nuclear medicine market in 2023. The high installed base of SPECT/PET scanners in hospitals is a key reason for the higher number of nuclear medicine procedures being conducted in hospitals. This in turn leads to a higher demand for diagnostic radiopharmaceuticals in hospitals. According to an article published by World Nuclear Association, over 10,000 hospitals worldwide use radioisotopes for diagnostic purposes. Technetium-99 is the most commonly used diagnostic radioisotope in diagnostics with over 40 million procedures being conducted every year.

The hospitals segment is expected to grow at a CAGR of 13.8% during the forecast period. Most of the therapeutic nuclear medicine procedures are conducted in hospitals. The recent approval of multiple therapeutic radioisotopes such as Pluvicto, Lutathera and several other products in pipeline such as Lu 177 PSMA I&T and Lu 177 edotreotide are expected to drive the segment.

Regional Insights

North America dominated the market with a revenue share of 46.48% in 2023 and is anticipated to grow at a significant rate over the forecast period. The high market share in the region can be attributed to the increased investment in R&D activities, high volume of nuclear medicine procedures, and strong healthcare infrastructure. For instance, in January 2021, Eckert & Ziegler announced the development plan of a cGMP facility for contract manufacturing of radiopharmaceuticals in Boston, U.S. The facility will be dedicated to the production of late-investigational-stage and commercial-stage radioisotopes used in nuclear medicines and can help address the increasing demand for radionuclides in market.

Nuclear Medicine Market Trends, by Region, 2023 - 2030

Asia Pacific region is estimated to be the fastest-growing region owing to increased awareness about nuclear medicine therapies and rising investment in nuclear medicine space. For instance, in March 2022, Penang Adventist Hospital (PAH) announced the launch of private nuclear medicine center in northern part of Thailand. This launch is anticipated to have positive impact on the Asian Market. However, high cost associated with these therapies may restrain the market growth as the lower-income group of population in developing countries may not afford such treatment. For instance, the cost of treatment with Yttrium-90,  Lutetium-177, and Iodine-131 may account for approximately USD 23,850, USD 5,962, and USD 3,312 respectively  in India.

Key Companies & Market Share Insights

Some of the key players operating in the industry are Eckert & Ziegler; Mallinckrodt; GE Healthcare; Nordion (Canada), Inc.; NTP Radioisotopes SOC Ltd. The leading players in radiation oncology industry are focusing on growth strategies, such as innovations with radiotherapy, product launches, and R&D investments.

Telix Pharmaceuticals, Inc.; Nordic Nanovector; Y-mAbs Therapeutics, Inc.are some of the emerging market participants in the radiation oncology space. Emerging companies are employing various strategies such as mergers & acquisitions to expand their footprint and grow at a fast pace.

Key Nuclear Medicine Companies:

  • GE Healthcare
  • Jubilant Life Sciences Ltd
  • Nordion (Canada), Inc.
  • Bracco Imaging S.P.A
  • The institute for radioelements (IRE)
  • NTP Radioisotopes SOC Ltd.
  • The Australian Nuclear Science and Technology Organization
  • Eczacıbaşı-Monrol
  • Lantheus Medical Imaging, Inc
  • Eckert & Ziegler
  • Mallinckrodt
  • Cardinal Health

Recent Developments

  • In April 2023, the U.S. FDA approved Novartis’ Milburn facility for the commercial production of Pluvicto.

  • In January 2023, NorthStar Medical Radioisotopes has notably progressed its technology to produce molybdenum-99 without uranium. This strategic move positions the company at the forefront of the nuclear medicine market, addressing critical supply chain issues.

Nuclear Medicine Market Report Scope 

Report Attribute

Details

Market size value in 2024

USD 11.34 billion

Revenue forecast in 2030

USD 22.3 billion

Growth rate

CAGR of 11.8% from 2024 to 2030

Actual data

2018 - 2023

Historical data

2018 - 2022

Forecast period

2024 - 2030

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; Russia, Netherlands; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Singapore; Thailand; Philippines; New Zealand; Malaysia, Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait; Turkey; Israel

Key companies profiled

Eckert & Ziegler; Mallinckrodt; GE Healthcare; Jubilant Life Sciences Ltd.; Nordion (Canada), Inc.; Bracco Imaging S.P.A.; IRE, the Australian Nuclear Science and Technology Organization; NTP Radioisotopes SOC Ltd.; Eczacıbaşı-Monrol; Lantheus Medical Imaging, Inc.; Cardinal Health

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

 

Global Nuclear Medicine Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the nuclear medicine market on the basis of product, application, end-use, and regions:

Global Nuclear Medicine Market Report Segmentation

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Diagnostic Products

      • SPECT

        • TC-99m

        • TL-201

        • GA-67

        • I-123

        • Other SPECT Products

      • PET

        • F-18

        • SR-82/RB-82

        • Other PET products

    • Therapeutic Products

      • Alpha Emitters

        • RA-223

        • Others

      • Beta Emitters

        • I-131

        • Y-90

        • SM-153

        • Re-186

        • Lu-117

        • Other Beta Emitters

      • Brachytherapy

        • Cesium-131

        • Iodine-125

        • Palladium-103

        • Iridium-192

        • Other Brachytherapy Products

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Cardiology

    • Neurology

    • Oncology

    • Thyroid

    • Lymphoma

    • Bone Metastasis

    • Endocrine Tumor

    • Others

  • End-use Outlook (Revenue, USD Million, 2018 - 2030)

    • Hospitals & Clinics

    • Diagnostic Centers

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Russia

      • Netherlands

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Singapore

      • New Zealand

      • Thailand

      • Philippines

      • Malaysia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Israel

      • Saudi Arabia

      • UAE

      • Turkey

      • Kuwait

Frequently Asked Questions About This Report

Table of Contents

Chapter 1 Research Methodology
                  1.1 Market Segmentation And Scope
                      1.1.1 Segment Definitions
                      1.1.3 Estimates And Forecast Timeline:
                  1.2 Research Methodology
                  1.3 Information Procurement
                      1.3.1 Purchased Database:
                      1.3.2 GVR’s Internal Database
                      1.3.3 Secondary Sources
                      1.3.4 Primary Research
                      1.3.5 Details Of Primary Research
                  1.4 Information Or Data Analysis
                      1.4.1 Data Analysis Models
                  1.5 Market Formulation & Validation
                  1.6 Model Details
                      1.6.1 Commodity Flow Analysis
                          1.6.1.1 Approach: Commodity Flow Approach
                  1.7 List Of Secondary Sources
                  1.8 List Of Abbreviations
                  1.9 Objectives
Chapter 2 Executive Summary
                  2.1 Market Summary
                      2.2.1 Segment Outlook
                      2.2.2 Regional Outlook
                      2.3.3 Competitive Insights
Chapter 3 Industry Outlook
                  3.1 Market Lineage Outlook
                      3.1.1 Parent Market Outlook
                      3.1.2 Related/ancillary Market Outlook
                  3.2 Market Dynamics
                      3.2.1 Market Driver Analysis
                          3.2.1.1 Rising Incidence Of Cancer And Cardiovascular Diseases
                          3.2.1.2 Increasing Application Of Radiopharmaceuticals/nuclear Medicine
                          3.2.1.3 Growing Demand For Accurate Diagnostic Methods
                      3.2.2 Market Restraint Analysis
                          3.2.2.1 Stringent Regulations Pertaining To Production, Storage, & Usage
                  3.3 Market Analysis Tools
                      3.3.1 Industry Analysis - Porter’s
                          3.3.1.1 Supplier Power
                          3.3.1.2 Buyer Power
                          3.3.1.3 Substitution Threat
                          3.3.1.4 Threat Of New Entrant
                          3.3.1.5 Competitive Rivalry
                      3.3.2 Pestel Analysis
                          3.3.2.1 Political Landscape
                          3.3.2.2 Technological Landscape
                          3.3.2.3 Economic Landscape
Chapter 4 Product Business Analysis
                  4.1 Nuclear Medicine Market: Product Movement Analysis
                  4.2 Diagnostic Products
                      4.2.1 Diagnostic Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.2.1.1 Spect
                              4.2.1.1.1 Spect Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.1.2 Tc-99m
                              4.2.1.1.3 Tc-99m Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.1.4 Tl-201
                              4.2.1.1.5 Tl-201 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.1.6 Ga-67
                              4.2.1.1.7 Ga-67 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.1.8 I-123
                              4.2.1.1.9 I-123 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.1.10 Other Spect Products
                              4.2.1.1.11 Other Spect Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.2.1.2 Pet
                              4.2.1.2.1 Pet Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.2.2 F-18
                              4.2.1.2.3 F-18 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.2.4 Sr-82/rb-82
                              4.2.1.2.5 Sr-82/rb-82 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.2.1.2.6 Other Pet Products
                              4.2.1.2.7 Other Pet Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
                  4.3 Therapeutic Products
                      4.3.1 Therapeutic Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      4.3.2 Alpha Emitters
                          4.3.2.1 Alpha Emitters Market Estimates And Forecast, 2018 - 2030 (USD Million)
                              4.3.2.1.1 Ra-223
                                  4.3.2.1.1.1 Ra-223 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      4.3.3 Beta Emitters
                          4.3.3.1 Beta Emitters Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.3.2 I-131
                              4.3.3.2.1 I-131 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.3.3 Y-90
                              4.3.3.3.1 Y-90 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.3.4 Sm-153
                              4.3.3.4.1 Sm-153 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.3.5 Re-186
                              4.3.3.5.1 Re-186 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.3.6 Lu-177
                              4.3.3.4.1 Lu-177 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.3.7 Other Beta Emitters
                              4.3.3.7.1 Other Beta Emitters Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      4.3.4 Brachytherapy
                          4.3.4.1 Brachytherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.4.2 Cesium-131
                              4.3.4.2.1 Cesium-131 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.4.3 Iodine-125
                              4.3.4.3.1 Iodine-125 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.4.4 Palladium-103
                              4.3.4.4.1 Palladium-103 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.4.5 Iridium-192
                              4.3.4.5.1 Iridium-192 Market Estimates And Forecast, 2018 - 2030 (USD Million)
                          4.3.4.6 Other Brachytherapy Products
                              4.3.4.4.1 Other Brachytherapy Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Application Business Analysis
                  5.1 Nuclear Medicine: Application Movement Analysis
                      5.1.1 Cardiology
                          5.1.1.1 Cardiology Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.2 Neurology
                          5.1.2.1 Neurology Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.3 Oncology
                          5.1.3.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.4 Thyroid
                          5.1.4.1 Thyroid Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.5 Lymphoma
                          5.1.5.1 Lymphoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.6 Bone Metastasis
                          5.1.6.1 Bone Metastasis Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.7 Endocrine Tumor
                          5.1.5.1 Endocrine Tumor Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      5.1.8 Other Application
                          5.1.8.1 Other Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 End-use Business Analysis
                  6.1 Nuclear Medicine: End-use Movement Analysis
                      6.1.1 Hospitals & Clinics
                          6.1.1.1 Hospitals & Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      6.1.2 Diagnostics Centers
                          6.1.2.1 Diagnostic Centers Market Estimates And Forecast, 2018 - 2030 (USD Million)
                      6.1.3 Others
                          6.1.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Regional Business Analysis
                  7.1 Nuclear Medicine Market: Regional Outlook
                  7.2 North America
                      7.2.1 North America Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                      7.2.2 U.S.
                          7.2.2.1 Key Country Dynamics
                          7.2.2.2 U.S. Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.2.2.3 Target Disease Prevalence
                          7.2.2.5 Competitive Scenario
                          7.2.2.6 Regulatory Framework
                          7.2.2.7 Reimbursement Scenario
                      7.2.3 Canada
                          7.2.3.1 Key Country Dynamics
                          7.2.3.2 Canada Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.2.3.3 Target Disease Prevalence
                          7.2.3.4 Competitive Scenario
                          7.2.3.5 Regulatory Framework
                          7.2.3.6 Reimbursement Scenario
                  7.3 Europe
                      7.3.1 Europe Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                      7.3.2 U.K.
                          7.3.2.1 Key Country Dynamics
                          7.3.2.2 U.K. Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.2.3 Target Disease Prevalence
                          7.3.2.4 Competitive Scenario
                          7.3.2.5 Regulatory Framework
                          7.3.2.6 Reimbursement Scenario
                      7.3.3 Germany
                          7.3.3.1 Key Country Dynamics
                          7.3.3.2 Germany Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.3.3 Target Disease Prevalence
                          7.3.3.4 Competitive Scenario
                          7.3.3.5 Regulatory Framework
                          7.3.3.6 Reimbursement Scenario
                      7.3.4 France
                          7.3.4.1 Key Country Dynamics
                          7.3.4.2 France Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.4.3 Target Disease Prevalence
                          7.3.4.4 Competitive Scenario
                          7.3.4.5 Regulatory Framework
                          7.3.4.6 Reimbursement Scenario
                      7.3.5 Italy
                          7.3.5.1 Key Country Dynamics
                          7.3.5.2 Italy Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.5.3 Target Disease Prevalence
                          7.3.5.4 Competitive Scenario
                          7.3.5.5 Regulatory Framework
                          7.3.5.6 Reimbursement Scenario
                      7.3.6 Spain
                          7.3.6.1 Key Country Dynamics
                          7.3.6.2 Spain Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.6.3 Target Disease Prevalence
                          7.3.6.4 Competitive Scenario
                          7.3.6.5 Regulatory Framework
                          7.3.6.6 Reimbursement Scenario
                      7.3.7 Denmark
                          7.3.7.1 Key Country Dynamics
                          7.3.7.2 Denmark Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.7.3 Target Disease Prevalence
                          7.3.7.4 Competitive Scenario
                          7.3.7.5 Regulatory Framework
                          7.3.7.6 Reimbursement Scenario
                      7.3.8 Sweden
                          7.3.8.1 Key Country Dynamics
                          7.3.8.2 Sweden Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.8.3 Target Disease Prevalence
                          7.3.8.4 Competitive Scenario
                          7.3.8.5 Regulatory Framework
                          7.3.8.6 Reimbursement Scenario
                      7.3.9 Norway
                          7.3.7.1 Key Country Dynamics
                          7.3.7.2 Norway Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.7.3 Target Disease Prevalence
                          7.3.7.4 Competitive Scenario
                          7.3.7.5 Regulatory Framework
                          7.3.7.6 Reimbursement Scenario
                      7.3.10 Russia
                          7.3.10.1 Key Country Dynamics
                          7.3.10.2 Russia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.10.3 Target Disease Prevalence
                          7.3.10.4 Competitive Scenario
                          7.3.10.5 Regulatory Framework
                          7.3.10.6 Reimbursement Scenario
                      7.3.11 Netherlands
                          7.3.11.1 Key Country Dynamics
                          7.3.11.2 The Netherlands Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.3.11.3 Target Disease Prevalence
                          7.3.11.4 Competitive Scenario
                          7.3.11.5 Regulatory Framework
                          7.3.11.6 Reimbursement Scenario
                  7.4 Asia Pacific
                      7.4.1 Asia Pacific Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                      7.4.2 Japan
                          7.4.2.1 Key Country Dynamics
                          7.4.2.2 Japan Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.2.3 Target Disease Prevalence
                          7.4.2.4 Competitive Scenario
                          7.4.2.5 Regulatory Framework
                          7.4.2.6 Reimbursement Scenario
                      7.4.3 China
                          7.4.3.1 Key Country Dynamics
                          7.4.3.2 China Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.3.3 Target Disease Prevalence
                          7.4.3.4 Competitive Scenario
                          7.4.3.5 Regulatory Framework
                          7.4.3.6 Reimbursement Scenario
                      7.4.4 India
                          7.4.4.1 Key Country Dynamics
                          7.4.4.2 India Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.4.3 Target Disease Prevalence
                          7.4.4.4 Competitive Scenario
                          7.4.4.5 Regulatory Framework
                          7.4.4.6 Reimbursement Scenario
                      7.4.5 Australia
                          7.4.5.1 Key Country Dynamics
                          7.4.5.2 Australia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.5.3 Target Disease Prevalence
                          7.4.5.4 Competitive Scenario
                          7.4.5.5 Regulatory Framework
                          7.4.5.6 Reimbursement Scenario
                      7.4.6 South Korea
                          7.4.6.1 Key Country Dynamics
                          7.4.6.2 South Korea Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.6.3 Target Disease Prevalence
                          7.4.6.4 Competitive Scenario
                          7.4.6.5 Regulatory Framework
                          7.4.6.6 Reimbursement Scenario
                      7.4.7 Thailand
                          7.4.7.1 Key Country Dynamics
                          7.4.7.2 Thailand Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.7.3 Target Disease Prevalence
                          7.4.7.4 Competitive Scenario
                          7.4.7.5 Regulatory Framework
                          7.4.7.6 Reimbursement Scenario
                      7.4.8 Philippines
                          7.4.8.1 Key Country Dynamics
                          7.4.8.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.8.3 Target Disease Prevalence
                          7.4.8.4 Competitive Scenario
                          7.4.8.5 Regulatory Framework
                          7.4.8.6 Reimbursement Scenario
                      7.4.9 Singapore
                          7.4.7.1 Key Country Dynamics
                          7.4.7.2 New Zealand Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.7.3 Target Disease Prevalence
                          7.4.7.4 Competitive Scenario
                          7.4.7.5 Regulatory Framework
                          7.4.7.6 Reimbursement Scenario
                      7.4.10 Malaysia
                          7.4.10.1 Key Country Dynamics
                          7.4.10.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.10.3 Target Disease Prevalence
                          7.4.10.4 Competitive Scenario
                          7.4.10.5 Regulatory Framework
                          7.4.10.6 Reimbursement Scenario
                      7.4.11 New Zealand
                          7.4.11.1 Key Country Dynamics
                          7.4.11.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.11.3 Target Disease Prevalence
                          7.4.11.4 Competitive Scenario
                          7.4.11.5 Regulatory Framework
                          7.4.11.6 Reimbursement Scenario
                  7.5 Latin America
                      7.5.1 Latin America Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                      7.5.2 Brazil
                          7.5.2.1 Key Country Dynamics
                          7.5.2.2 Brazil Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.5.2.3 Target Disease Prevalence
                          7.5.2.4 Competitive Scenario
                          7.5.2.5 Regulatory Framework
                          7.5.2.6 Reimbursement Scenario
                      7.5.3 Mexico
                          7.5.3.1 Key Country Dynamics
                          7.5.3.2 Mexico Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.5.3.3 Target Disease Prevalence
                          7.5.3.4 Competitive Scenario
                          7.5.3.5 Regulatory Framework
                          7.5.3.6 Reimbursement Scenario
                      7.5.4 Argentina
                          7.5.4.1 Key Country Dynamics
                          7.5.4.2 Argentina Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.5.4.3 Target Disease Prevalence
                          7.5.4.4 Competitive Scenario
                          7.5.4.5 Regulatory Framework
                          7.5.4.6 Reimbursement Scenario
                  7.6 Middle East And Africa
                      7.6.1 Middle East And Africa Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
                          7.6.1.1 Target Disease Prevalence
                          7.6.1.2 Competitive Scenario
                          7.6.1.3 Regulatory Framework
                          7.6.1.4 Reimbursement Scenario
                      7.6.2 South Africa
                          7.6.2.1 Key Country Dynamics
                          7.6.2.2 South Africa Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.6.2.3 Target Disease Prevalence
                          7.6.2.4 Competitive Scenario
                          7.6.2.5 Regulatory Framework
                          7.6.2.6 Reimbursement Scenario
                      7.6.3 Saudi Arabia
                          7.6.3.1 Key Country Dynamics
                          7.6.3.2 Saudi Arabia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.6.3.3 Target Disease Prevalence
                          7.6.3.4 Competitive Scenario
                          7.6.3.5 Regulatory Framework
                          7.6.3.6 Reimbursement Scenario
                      7.6.4 UAE
                          7.6.4.1 Key Country Dynamics
                          7.6.4.2 UAE Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.6.4.3 Target Disease Prevalence
                          7.6.4.4 Competitive Scenario
                          7.6.4.5 Regulatory Framework
                          7.6.4.6 Reimbursement Scenario
                      7.6.5 Kuwait
                          7.6.5.1 Key Country Dynamics
                          7.6.5.2 Kuwait Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.6.5.3 Target Disease Prevalence
                          7.6.5.4 Competitive Scenario
                          7.6.5.5 Regulatory Framework
                          7.6.5.6 Reimbursement Scenario
                      7.4.6 Israel
                          7.4.6.1 Key Country Dynamics
                          7.4.6.2 Israel Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.6.3 Target Disease Prevalence
                          7.4.6.4 Competitive Scenario
                          7.4.6.5 Regulatory Framework
                          7.4.6.6 Reimbursement Scenario
                      7.4.7 Turkey
                          7.4.7.1 Key Country Dynamics
                          7.4.7.2 Turkey Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
                          7.4.7.3 Target Disease Prevalence
                          7.4.7.4 Competitive Scenario
                          7.4.7.5 Regulatory Framework
                          7.4.7.6 Reimbursement Scenario
Chapter 8 Company Profiles
                  8.1 Company Categorization
                  8.2 Strategy Mapping
                      8.2.1 New Product Launch
                      8.2.2 Partnerships
                      8.2.3 Acquisition
                      8.2.4 Collaboration
                      8.2.5 Funding
                  8.3 Key Company Market Share Analysis, 2022
                  8.4 Company Profiles
                      8.4.1 Eckert & Ziegler
                          8.4.1.1 Company Overview
                          8.4.1.2 Financial Performance
                          8.4.1.3 Product Benchmarking
                          8.4.1.4 Strategic Initiatives
                      8.4.2 Mallinckrodt
                          8.4.2.1 Company Overview
                          8.4.2.2 Financial Performance
                          8.4.2.3 Product Benchmarking
                          8.4.2.4 Strategic Initiatives
                      8.4.3 Curium Pharma
                          8.4.3.1 Company Overview
                          8.4.3.2 Financial Performance
                          8.4.3.3 Product Benchmarking
                          8.4.3.4 Strategic Initiatives
                      8.4.4 General Electric
                          8.4.4.1 Company Overview
                          8.4.4.2 Financial Performance
                          8.4.4.3 Product Benchmarking
                          8.4.4.4 Strategic Initiatives
                      8.4.5 Jubilant Life Sciences Ltd.
                          8.4.5.1 Company Overview
                          8.4.5.2 Financial Performance
                          8.4.5.3 Product Benchmarking
                          8.4.5.4 Strategic Initiatives
                      8.4.6 Bracco Imaging S.p.a.
                          8.4.6.1 Company Overview
                          8.4.6.2 Financial Performance
                          8.4.6.3 Product Benchmarking
                          8.4.6.4 Strategic Initiatives
                      8.4.7 Nordion (Canada), Inc.
                          8.4.7.1 Company Overview
                          8.4.7.2 Financial Performance
                          8.4.7.3 Product Benchmarking
                          8.4.7.4 Strategic Initiatives
                      8.4.8 The Institute For Radioelements (Ire - Ire Elit - Be)
                          8.4.8.1 Company Overview
                          8.4.8.2 Financial Performance
                          8.4.8.3 Product Benchmarking
                          8.4.8.4 Strategic Initiatives
                      8.4.9 Australian Nuclear Science & Technology Organization (Ansto)
                          8.4.9.1 Company Overview
                          8.4.9.2 Financial Performance
                          8.4.9.3 Product Benchmarking
                          8.4.9.4 Strategic Initiatives
                      8.4.10 Ntp Radioisotopes Soc Ltd.
                          8.4.8.1 Company Overview
                          8.4.8.2 Financial Performance
                          8.4.8.3 Product Benchmarking
                          8.4.8.4 Strategic Initiatives
                      8.4.11 Eczacibaşi-monrol
                          8.4.11.1 Company Overview
                          8.4.11.2 Financial Performance
                          8.4.11.3 Product Benchmarking
                          8.4.11.4 Strategic Initiatives
                      8.4.12 Lantheus Medical Imaging, Inc.
                          8.4.12.1 Company Overview
                          8.4.12.2 Financial Performance
                          8.4.12.3 Product Benchmarking
                          8.4.12.4 Strategic Initiatives
                      8.4.13 Cardinal Health
                          8.4.13.1 Company Overview
                          8.4.13.2 Financial Performance
                          8.4.13.3 Product Benchmarking
                          8.4.13.4 Strategic Initiatives
                      8.4.14 Novartis Ag
                          8.4.14.1 Company Overview
                          8.4.14.2 Financial Performance
                          8.4.14.3 Product Benchmarking
                          8.4.14.4 Strategic Initiatives
                      8.4.15 Bayer Ag
                          8.4.15.1 Company Overview
                          8.4.15.2 Financial Performance
                          8.4.15.3 Product Benchmarking
                          8.4.15.4 Strategic Initiatives
                      8.4.16 Point Biopharma Global Inc.
                          8.4.16.1 Company Overview
                          8.4.16.2 Financial Performance
                          8.4.16.3 Product Benchmarking
                          8.4.16.4 Strategic Initiatives
                      8.4.17 Telix Pharmaceuticals
                          8.4.17.1 Company Overview
                          8.4.17.2 Financial Performance
                          8.4.17.3 Product Benchmarking
                          8.4.17.4 Strategic Initiatives
                      8.4.18 Actinium Pharmaceuticals, Inc
                          8.4.18.1 Company Overview
                          8.4.18.2 Financial Performance
                          8.4.18.3 Product Benchmarking
                          8.4.18.4 Strategic Initiatives
                      8.4.19 Iba Group
                          8.4.19.1 Company Overview
                          8.4.19.2 Financial Performance
                          8.4.19.3 Product Benchmarking
                          8.4.19.4 Strategic Initiatives
                      8.4.20 Sirtex Medical
                          8.4.20.1 Company Overview
                          8.4.20.2 Financial Performance
                          8.4.20.3 Product Benchmarking
                          8.4.20.4 Strategic Initiatives
Chapter 9 Analyst Perspective


List of Tables

Table 1 Global Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 2 Global Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 3 Global Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 4 Global Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 5 North America Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 6 North America Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 7 North America Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 8 North America Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 9 U.S. Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 10 U.S. Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 11 U.S. Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 12 Canada Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 13 Canada Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 14 Canada Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 15 Europe Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 16 Europe Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 18 Europe Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 19 UK Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 20 UK Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 21 UK Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 22 Germany Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 23 Germany Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 24 Germany Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 25 France Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 26 France Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 27 France Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 28 Italy Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 29 Italy Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 30 Italy Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 31 Spain Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 32 Spain Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 33 Spain Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 34 Russia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 35 Russia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 36 Russia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 37 Netherlands Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 38 Netherlands Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 39 Netherlands Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 40 Denmark Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 41 Denmark Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 42 Denmark Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 43 Sweden Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 44 Sweden Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 45 Sweden Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 46 Norway Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 47 Norway Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 48 Norway Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 52 Asia Pacific Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 53 Japan Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 54 Japan Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 55 Japan Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 56 China Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 57 China Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 58 China Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 59 India Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 60 India Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 61 India Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 62 Australia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 63 Australia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 64 Australia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 65 Singapore Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 66 Singapore Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 67 Singapore Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 68 South Korea Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 69 South Korea Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 70 South Korea Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 71 Thailand Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 72 Thailand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 73 Thailand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 74 Philippines Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 75 Philippines Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 76 Philippines Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 77 New Zealand Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 78 New Zealand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 79 New Zealand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 80 Malaysia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 81 Malaysia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 82 Malaysia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 83 Latin America Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 84 Latin America Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 85 Latin America Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 86 Latin America Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 87 Brazil Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 88 Brazil Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 89 Brazil Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 90 Mexico Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 91 Mexico Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 92 Mexico Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 93 Argentina Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 94 Argentina Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 95 Argentina Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 96 Middle East & Africa Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 97 Middle East & Africa Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 98 Middle East & Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 99 Middle East & Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 100 South Africa Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 101 South Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 102 South Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 103 Saudi Arabia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 104 Saudi Arabia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 105 Saudi Arabia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 106 UAE Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 107 UAE Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 108 UAE Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 109 Turkey Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 110 Turkey Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 111 Turkey Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 112 Israel Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 113 Israel Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 114 Israel Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 115 Kuwait Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 116 Kuwait Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 117 Kuwait Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Nuclear medicine market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Nuclear Medicine market snapshot
Fig. 10 Nuclear Medicine market driver impact
Fig. 11 Global cancer cases projections - 2030 (Number of new registered cases)
Fig. 12 Nuclear Medicine market restraint impact
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Value chain analysis
Fig. 16 Nuclear Medicine Market: Production of Tc-99 (SPECT radioisotopes)
Fig. 17 Nuclear Medicine market: Production of 18F-FDG (PET radioisotopes)
Fig. 18 Company market share analysis
Fig. 19 Company market position analysis
Fig. 20 Company market position analysis
Fig. 21 Competitive dashboard analysis
Fig. 22 Regional network map
Fig. 23 Nuclear Medicine market: Product outlook and key takeaways
Fig. 24 Nuclear Medicine market: Product movement analysis
Fig. 25 Diagnostic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Therapeutic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Other beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Other brachytherapy products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Nuclear Medicine market: Application outlook and key takeaways
Fig. 53 Nuclear Medicine market: Application movement analysis
Fig. 54 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Thyroid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Bone metastasis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Endocrine tumor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Nuclear Medicine market: End-use outlook and key takeaways
Fig. 63 Nuclear Medicine market: End-use movement analysis
Fig. 64 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Diagnostic Centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Nuclear Medicine market: Regional outlook and key takeaways
Fig. 68 Nuclear Medicine market: Regional movement analysis
Fig. 69 North America SWOT analysis
Fig. 70 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 U.S. key country dynamics
Fig. 72 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Canada key country dynamics
Fig. 74 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Europe SWOT analysis
Fig. 76 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 UK key country dynamics
Fig. 78 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Germany key country dynamics
Fig. 80 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Italy key country dynamics
Fig. 82 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Spain key country dynamics
Fig. 84 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 France key country dynamics
Fig. 86 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Russia key country dynamics
Fig. 88 Russia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Netherlands key country dynamics
Fig. 88 Netherlands market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Denmark key country dynamics
Fig. 90 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Sweden key country dynamics
Fig. 92 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Norway key country dynamics
Fig. 94 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Asia Pacific SWOT analysis
Fig. 96 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Japan key country dynamics
Fig. 98 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 China key country dynamics
Fig. 100 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 India key country dynamics
Fig. 102 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Singapore key country dynamics
Fig. 104 Singapore market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Australia key country dynamics
Fig. 106 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 107 South Korea key country dynamics
Fig. 108 8 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 109 Thailand key country dynamics
Fig. 110 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 111 Philippines key country dynamics
Fig. 112 Philippines market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 113 New Zealand key country dynamics
Fig. 114 New Zealand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 115 Malaysia key country dynamics
Fig. 116 Malaysia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 117 Latin America SWOT analysis
Fig. 118 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 119 Brazil key country dynamics
Fig. 120 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 121 Mexico key country dynamics
Fig. 122 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 123 Argentina key country dynamics
Fig. 124 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 125 Middle East & Africa SWOT analysis
Fig. 126 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 127 South Africa key country dynamics
Fig. 128 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 129 Saudi Arabia key country dynamics
Fig. 130 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 131 UAE key country dynamics
Fig. 132 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 133 Israel key country dynamics
Fig. 134 Israel market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 135 Turkey key country dynamics
Fig. 136 Turkey market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 137 Kuwait key country dynamics
Fig. 138 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 139 Company Market Position Analysis

What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Market Segmentation 

  • Global Nuclear Medicine Market: Product Outlook (Revenue, USD Million, 2018 - 2030)
    • Diagnostic Products
      • SPECT
        • TC-99m
        • TL-201
        • GA-67
        • I-123
        • Other SPECT products
      • PET
        • F-18
        • SR-82/RB-82
        • Other PET products
    • Therapeutic Products
      • Alpha Emitters
        • RA-223
        • Others
      • Beta Emitters
        • I-131
        • Y-90
        • SM-153
        • Re-186
        • Lu-117 
        • Other beta emitters
      • Brachytherapy
        • Cesium-131
        • Iodine-125
        • Palladium-103
        • Iridium-192
        • Other brachytherapy products
  • Global Nuclear Medicine Market: Application Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Cardiology
    • Neurology
    • Oncology
    • Thyroid
    • Lymphoma
    • Bone Metastasis
    • Endocrine Tumor
    • Others
  • Global Nuclear Medicine Market: End-use Outlook (Revenue, USD Million, 2018 - 2030)
    • Hospitals & Clinics
    • Diagnostic Centers
    • Others
  • Global Nuclear Medicine: Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • U.S.
        • U.S. Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • U.S. Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • U.S. Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Canada
        • Canada Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Canada Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Canada Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
    • Europe
      • UK
        • UK Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • UK Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • UK Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Germany
        • Germany Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Germany Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Germany Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • France
        • France Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • France Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • France Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Italy
        • Italy Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Italy Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Italy Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Spain
        • Spain Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Spain Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Spain Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Russia
        • Russia Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Russia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Russia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Netherlands
        • Netherlands Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Netherlands Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Netherlands Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Denmark
        • Denmark Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Denmark Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Denmark Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Sweden
        • Sweden Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Sweden Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Sweden Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Norway
        • Norway Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Norway Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Norway Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
    • Asia Pacific
      • Japan
        • Japan Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Japan Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Japan Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • China
        • China Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • China Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • China Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • India
        • India Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • India Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • India Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Australia
        • Australia Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Australia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Australia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • South Korea
        • South Korea Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • South Korea Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • South Korea Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Singapore
        • Singapore Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Singapore Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Singapore Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Thailand
        • Thailand Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Thailand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Thailand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Philippines
        • Philippines Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Philippines Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Philippines Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • New Zealand
        • New Zealand Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • New Zealand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • New Zealand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Malaysia
        • Malaysia Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Malaysia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Malaysia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
    • Latin America
      • Brazil
        • Brazil Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Brazil Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Brazil Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Mexico
        • Mexico Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Mexico Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Mexico Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Argentina
        • Argentina Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Argentina Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Argentina Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
    • MEA
      • South Africa
        • South Africa Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • South Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • South Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Saudi Arabia
        • Saudi Arabia Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Saudi Arabia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Saudi Arabia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • UAE
        • UAE Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • UAE Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • UAE Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Turkey
        • Turkey Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Turkey Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Turkey Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Israel
        • Israel Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Israel Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Israel Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others
      • Kuwait
        • Kuwait Nuclear Medicine Market, By Product 2018 - 2030 (USD Million)
          • Diagnostic products
            • SPECT
              • TC-99m
              • TL-201
              • GA-67
              • I-123
              • Other SPECT products
            • PET
              • F-18
              • SR-82/RB-82
              • Other PET products
          • Therapeutic Products
            • Alpha Emitters
              • RA-223
              • Others
            • Beta Emitters
              • I-131
              • Y-90
              • SM-153
              • Re-186
              • Lu-117 
              • Other beta emitters
            • Brachytherapy
              • Cesium-131
              • Iodine-125
              • Palladium-103
              • Iridium-192
              • Other brachytherapy products
        • Kuwait Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
          • Cardiology
          • Neurology
          • Oncology
          • Thyroid
          • Lymphoma
          • Bone Metastasis
          • Endocrine Tumor
          • Others
        • Kuwait Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
          • Hospitals & Clinics
          • Diagnostic Centers
          • Others

Nuclear Medicine Market Dynamics

Driver - Rising Incidence of Cancer and Cardiovascular Diseases

Increasing demand for early and accurate diagnosis of diseases, coupled with growing demand for enhanced therapies, is expected to fuel the market. According to WHO, globally, cancer is the second leading cause of death. In 2020, the number of new cases reached 19.3 million and projected deaths due to cancer were at 9.96 million. According to the International Agency for Research on Cancer, the number of new cases is expected to reach 21.9 million by 2025. The top three cancers are lung (2.51 million cases), breast (2.46 million cases), and prostate (1.61 million cases). The number of new cases of cancer is expected to reach 24.6 million by 2030. This figure exhibits significant growth in the number of cancer cases worldwide. Moreover, the high prevalence of cancer in emerging Asian economies is creating a major demand for radiopharmaceuticals. According to GLOBOCAN, in 2020, approximately 49.2% of global cancer cases were registered in Asia. Thus, this region remains a vast untapped market for radiopharmaceuticals.

Driver - Increasing Application of Radiopharmaceuticals/Nuclear Medicine

Currently, radiopharmaceuticals are widely used in the fields of cardiology and oncology. Ongoing research & studies demonstrating positive results are expanding the application of radioisotopes in the diagnosis & treatment of cancer, thyroid-related diseases, respiratory diseases, bone diseases, and digestive tract conditions. For instance, in December 2019, a research team from Helmholtz-Zentrum Dresden-Rossendorf (HZDR) published a study on [18F] FACH, to diagnose tumor-relevant transport proteins. They developed 18F-radiolabeled MCT1/MCT4 inhibitor FACH (Monocarboxylate transporters 1 and 4) from a one-step synthesis to visualize special transport proteins found in the membranes of cancer cells. It was found that the new procedure gives high radiochemical yields of 43 ± 8% with reduced synthesis time. Furthermore, the radiosynthesis was transferred to the TRACERlab FX2 N system for future preclinical applications of [18F] FACH. Technetium-99m is one of the most commonly used radioisotopes in radiopharmaceuticals. Other widely used radioisotopes include Iodine-131, Indium-111, and Fluorine-18. These medical isotopes are also commonly used in radiopharmacology to study drug movement in lab subjects.

Restraint - Stringent Regulations Pertaining to Production, Storage, and Usage

Radioactive substances are capable of mutating genes and may cause severe adverse effects, including fatalities. Thus, handling radioactive substances is strictly regulated by governments to ensure compliance with radiation safety policies. Approval procedures for products containing radioactive substances are stringent, which delays their launch in the market. In addition, regulations mandate the hiring of skilled professionals for the installation and operation of instruments involving radioactive materials. Thus, stringent government regulations are likely to limit market growth during the forecast period. Moreover, the U.S. has made efforts to minimize the export of Highly Enriched Uranium (HEU) used for the production of medical radioisotopes as part of its nuclear non-proliferation objectives and subsequently increased efforts for the production of medical isotopes using low-enriched uranium, resulting in higher costs of production.

What Does This Report Include?

This section will provide insights into the contents included in this nuclear medicine market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Nuclear medicine market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Nuclear medicine market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Research Methodology

A three-pronged approach was followed for deducing the nuclear medicine market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for nuclear medicine market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of nuclear medicine market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Nuclear Medicine Market Categorization:

The nuclear medicine market was categorized into four segments, namely product (Diagnostic Products, Therapeutic Products), application (Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor), end-use (Hospitals & Clinics, Diagnostic Centers), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The nuclear medicine market was segmented into product, application, end-use and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The nuclear medicine market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into thirty-one countries, namely, the U.S.; Canada; Germany; the UK.; France; Italy; Spain; Russia, Netherlands; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Singapore; Thailand; Philippines; New Zealand; Malaysia, Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait; Turkey; Israel.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Nuclear medicine market companies & financials:

The nuclear medicine market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • Eckert & Ziegler, Eckert & Ziegler was established in 1997 and headquartered in the UK. The company manufactures & commercializes radiotherapy equipment and is a leading producer of brachytherapy products in Europe. It is one of the largest providers of isotope technology for scientific, industrial, and medical use. Its core business is to develop and distribute products for the treatment of cancers using brachytherapy. Other business units are industrial radiometry and nuclear medical imaging. Its production facilities are located in Germany and the U.S., with many subsidiaries in Europe. As of December 2020, the company had 828 employees and a global presence, including the UK, China, India, France, and Germany.

  • Mallinckrodt, Mallinckrodt specializes in developing, manufacturing, and marketing diagnostic imaging agents & specialty pharmaceutical products. The company was incorporated in 1867 and is headquartered in the UK. In 2000, Covidien Pharmaceutical acquired Mallinckrodt, Inc. and operated as its pharmaceutical business. However, in 2013, Mallinckrodt started operating as an independent publicly held company, not as a subsidiary of Covidien Plc. Mallinckrodt’s area of focus includes autoimmune & rare diseases and specialty areas, such as rheumatology, neurology, nephrology, ophthalmology, & pulmonology; immunotherapy & neonatal respiratory critical care therapies; and analgesics & gastrointestinal products. The company’s specialty generics and Amitiza segment comprises specialty generic drugs, API, Amitiza. As of December 2020, the company had 3,100 employees and more than 15 products in its pipeline.

  • Curium Pharma, Curium was founded by the IBA Molecular and Mallinckrodt Nuclear Medicine Union in 2017 and is headquartered in the UK. The two companies are major North American and European suppliers. Curium is engaged in developing, manufacturing, and distributing high-quality radiopharmaceutical products to cater to patients across the globe. The company delivers vital products to over 14 million patients, including PET, SPECT, and therapeutic radiopharmaceuticals, every year. As of May 2021, the company had 957 employees. CIS Bio International is a member of the Curium group, which operates the Basic Nuclear Installation No.29, Saclay nuclear site in France. The company focuses on developing, manufacturing, and commercializing radiopharmaceuticals for diagnosis & therapeutics in four areas: cardiology, neurology, oncology, & rheumatology.

  • General Electric, GE Healthcare is a business unit of General Electric Company, established in 1994 and headquartered in the U.S. It manufactures & develops diagnostic solutions, bioprocessing, genomics, protein research, lab filtration, cellular therapy, and cell & gene therapy. The company offers services, such as technology solutions, for drug discovery, medical equipment, and solutions for clinicians & healthcare administrators. As of December 2020, the company had 174,000 employees and a presence in over 40 countries globally. Its Life Sciences business includes pharmaceuticals, diagnostics, & biopharmaceutics, and 100,000 biopharma systems, used worldwide.

  • Jubilant Life Sciences Ltd., Jubilant Pharma. LLC is a Jubilant Life Sciences Ltd. company that manufactures & supplies pharmaceutical and life science products, such as allergy therapy products, solid dosage formulations, nutrition products, radiopharmaceuticals, & life science chemicals. The company was established in 1978 and is headquartered in Noida, India. Jubilant Radiopharma is a subsidiary of Jubilant Pharma, dealing with a variety of radiopharmaceutical products. As of March 2020, the company had 2,554 employees and a presence in over 100 countries. Its customers include hospitals & individual patients. The company has six U.S. FDA-approved manufacturing facilities in the U.S., Canada, and India, with a network of 50 radiopharmacies in the U.S. It is recognized as a Partner of Choice by leading life science companies. It is located in India, the U.S., Canada, Belgium, Singapore, and China.

  • Bracco Imaging S.P.A., Bracco Imaging was incorporated in 1985 and is headquartered in Italy. The company is engaged in the discovery, development, manufacture, and marketing of imaging solutions. Its portfolio includes pharmaceuticals and other health services. As of May 2021, the company had 1,578 employees and a presence in more than 20 countries through subsidiaries and sister companies. Its contrast agents are sold in 100 countries through joint ventures with licenses and distributions. The company invests around 10% of the imaging diagnostics and medical device sector turnover with 1,800 patents. Its commonly used products are contrast agents and medical substances. Contrast agents include radiographic procedures such as CT, MRI, and nuclear medicine.

  • Nordion (Canada), Inc., Nordion (Canada), Inc. offers products and services for the diagnosis, prevention, & treatment of diseases. The company was founded in 1946 and is headquartered in Canada. Its targeted therapies segment includes TheraSphere, a therapeutic medical device used to treat inoperable primary and metastatic liver cancer. The company is a leader in gamma technologies and medical isotopes. It also specializes in the fields of radiopharmaceuticals, production irradiators, and health sciences. It designs, constructs, installs, and maintains commercial gamma sterilization systems (used to sterilize surgical apparatus). It has a presence in around 40 countries and employs approximately 500 people.

  • The Institute for Radioelements (IRE - IRE ELIT - BE), IRE is a radiopharmaceutical company that produces radioisotopes for diagnostic and treatment applications in various fields of medicine. The company was incorporated in 1971 and is headquartered in Belgium. It operates in the radioelement industry across North America, Europe, Asia, the Middle East, and other regions. It employs over 200 people and is involved in manufacturing & production facilities and other services. Its quality control and management system comply with cGMP, ISO 9001, and ISO 17025 standards. It has undertaken strategic initiatives such as participation in NEA/OECD High-Level Group (HLG) on the security of supply of medical isotopes and BioWin Health Cluster of the Walloon region.

  • Australian Nuclear Science & Technology Organization (ANSTO), The Australian Nuclear Science and Technology Organization (ANSTO) is a government research organization that employs more than 1,000 scientists, engineers, and experts from various fields. It was established in 1987 and is headquartered in Australia. As of December 2020, the organization had 1,331 employees. It applies nuclear science processes in various fields, including environmental, medical, and industrial applications. ANSTO operates nuclear research reactors; a comprehensive suite of neutron beam instruments; the National Research Cyclotron; the Australian Synchrotron; the Centre for Accelerator Science, and the Open Pool Australian Lightwater (OPAL) reactor. The organization manufactures a range of radiopharmaceuticals labeled with radionuclides to help healthcare practitioners diagnose and treat diseased organs and tumors.

  • NTP Radioisotopes SOC Ltd.,NTP Radioisotopes SOC Ltd. was incorporated in 2003 and is headquartered in South Africa. It is a wholly-owned subsidiary of the South African Nuclear Energy Corporation (Necsa). It has operational facilities in South Africa at the Pelindaba nuclear facility. It supplies nearly one-third of the world’s Mo-99 and exports its products to around 50 countries. It produces and distributes other medical radioisotopes, including Iodine-131 and Lutetium-177. NTP Radioisotopes SOC Ltd. has established activities such as the construction of the SAFARI-1 nuclear reactor and South Africa’s nuclear research and technology program. The daughter products of Mo-99m and Tc-99m are used in more than 40 million diagnostic procedures annually.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Nuclear Medicine Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Nuclear Medicine Market Report Assumptions:

  • The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.